دورية أكاديمية
أعرض في EDS

Comparing the evidential strength for psychotropic drugs: a Bayesian meta-analysis.

التفاصيل البيبلوغرافية
العنوان: Comparing the evidential strength for psychotropic drugs: a Bayesian meta-analysis.
المؤلفون: Pittelkow MM; Department Psychometrics and Statistics, University of Groningen, Groningen, the Netherlands., de Vries YA; Department of Developmental Psychology, University of Groningen, Groningen, the Netherlands.; Interdisciplinary Center Psychopathology and Emotion Regulation, Department of Psychiatry, University Medical Center Groningen, Groningen, the Netherlands., Monden R; Interdisciplinary Center Psychopathology and Emotion Regulation, Department of Psychiatry, University Medical Center Groningen, Groningen, the Netherlands.; Department of Biomedical Statistics, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan., Bastiaansen JA; Interdisciplinary Center Psychopathology and Emotion Regulation, Department of Psychiatry, University Medical Center Groningen, Groningen, the Netherlands.; Department of Education and Research, Friesland Mental Health Care Services, Leeuwarden, the Netherlands., van Ravenzwaaij D; Department Psychometrics and Statistics, University of Groningen, Groningen, the Netherlands.
المصدر: Psychological medicine [Psychol Med] 2021 Dec; Vol. 51 (16), pp. 2752-2761. Date of Electronic Publication: 2021 Oct 08.
نوع المنشور: Meta-Analysis; Journal Article; Review; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Cambridge University Press Country of Publication: England NLM ID: 1254142 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1469-8978 (Electronic) Linking ISSN: 00332917 NLM ISO Abbreviation: Psychol Med Subsets: MEDLINE
أسماء مطبوعة: Publication: London : Cambridge University Press
Original Publication: London, British Medical Assn.
مواضيع طبية MeSH: Antipsychotic Agents*/therapeutic use , Attention Deficit Disorder with Hyperactivity*/drug therapy, Humans ; Bayes Theorem ; Psychotropic Drugs/therapeutic use ; Antidepressive Agents/therapeutic use
مستخلص: Approval and prescription of psychotropic drugs should be informed by the strength of evidence for efficacy. Using a Bayesian framework, we examined (1) whether psychotropic drugs are supported by substantial evidence (at the time of approval by the Food and Drug Administration), and (2) whether there are systematic differences across drug groups. Data from short-term, placebo-controlled phase II/III clinical trials for 15 antipsychotics, 16 antidepressants for depression, nine antidepressants for anxiety, and 20 drugs for attention deficit hyperactivity disorder (ADHD) were extracted from FDA reviews. Bayesian model-averaged meta-analysis was performed and strength of evidence was quantified (i.e. BF BMA ). Strength of evidence and trialling varied between drugs. Median evidential strength was extreme for ADHD medication ( BF BMA = 1820.4), moderate for antipsychotics ( BF BMA = 365.4), and considerably lower and more frequently classified as weak or moderate for antidepressants for depression ( BF BMA = 94.2) and anxiety ( BF BMA = 49.8). Varying median effect sizes ( ES schizophrenia = 0.45, ES depression = 0.30, ES anxiety = 0.37, ES ADHD = 0.72), sample sizes ( N schizophrenia = 324, N depression = 218, N anxiety = 254, N ADHD = 189.5), and numbers of trials ( k schizophrenia = 3, k depression = 5.5, k anxiety = 3, k ADHD = 2) might account for differences. Although most drugs were supported by strong evidence at the time of approval, some only had moderate or ambiguous evidence. These results show the need for more systematic quantification and classification of statistical evidence for psychotropic drugs. Evidential strength should be communicated transparently and clearly towards clinical decision makers.
References: N Engl J Med. 2008 Jan 17;358(3):252-60. (PMID: 18199864)
Int J Epidemiol. 2012 Jun;41(3):818-27. (PMID: 22461129)
JAMA Psychiatry. 2015 May;72(5):500-10. (PMID: 25806940)
J Affect Disord. 2018 Aug 1;235:393-398. (PMID: 29677603)
PLoS One. 2017 Mar 8;12(3):e0173184. (PMID: 28273140)
Stat Methods Med Res. 2021 May;30(5):1358-1372. (PMID: 33504274)
BMC Med. 2015 Oct 02;13:253. (PMID: 26431961)
Br J Psychiatry. 2016 Jun;208(6):515-21. (PMID: 26989093)
Lancet. 2019 Sep 14;394(10202):939-951. (PMID: 31303314)
BMC Med Res Methodol. 2019 Nov 27;19(1):218. (PMID: 31775644)
Regul Toxicol Pharmacol. 2019 Apr;103:174-180. (PMID: 30711621)
Ann Intern Med. 1999 Jun 15;130(12):1005-13. (PMID: 10383350)
Int J Methods Psychiatr Res. 2016 Dec;25(4):299-308. (PMID: 27219132)
Arch Gen Psychiatry. 2009 Aug;66(8):848-56. (PMID: 19652124)
Lancet. 2018 Apr 7;391(10128):1357-1366. (PMID: 29477251)
PLoS Med. 2012;9(3):e1001189. (PMID: 22448149)
Br J Psychiatry. 2012 May;200(5):393-8. (PMID: 22442100)
Psychol Med. 2018 Nov;48(15):2453-2455. (PMID: 30070192)
Aust N Z J Psychiatry. 2013 Jan;47(1):74-87. (PMID: 23144164)
JAMA Intern Med. 2017 Feb 1;177(2):274-275. (PMID: 27942726)
Lancet Psychiatry. 2018 Sep;5(9):727-738. (PMID: 30097390)
Trials. 2014 Sep 03;15:346. (PMID: 25187348)
J Grad Med Educ. 2012 Sep;4(3):279-82. (PMID: 23997866)
Stat Med. 2015 Mar 15;34(6):984-98. (PMID: 25475839)
EClinicalMedicine. 2020 Jan 07;18:100219. (PMID: 31993575)
Psychon Bull Rev. 2009 Apr;16(2):225-37. (PMID: 19293088)
فهرسة مساهمة: Keywords: Bayesian meta-analysis; drug endorsement; evidential strength; psychotropic drugs
المشرفين على المادة: 0 (Antipsychotic Agents)
0 (Psychotropic Drugs)
0 (Antidepressive Agents)
تواريخ الأحداث: Date Created: 20211008 Date Completed: 20221124 Latest Revision: 20231108
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8640368
DOI: 10.1017/S0033291721003950
PMID: 34620261
قاعدة البيانات: MEDLINE
الوصف
تدمد:1469-8978
DOI:10.1017/S0033291721003950